Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Journal of Immunology (Baltimore, Md. : 1950)|April 26, 2024
Generation of an Inhibitory NK Cell Subset by TGF-β1/IL-15 PolarizationDouglas C Chung, Carlos R Garcia-Batres, Douglas G Millar, et al.
Nature Communications|February 6, 2024
Tumor reactive γδ T cells contribute to a complete response to PD-1 blockade in a Merkel cell carcinoma patientScott C Lien, Dalam Ly, S Y Cindy Yang, et al.
Translational Oncology|August 24, 2025
Elucidating divergent biology in uterine carcinosarcomaVikas Garg, Stephenie D Prokopec, Simone C Stone, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 21, 2026
CD28-driven ex vivo generation of stem-like memory CD8<sup>+</sup> T cells bypassing CD3/TCR signalingFumie Ihara, Yota Ohashi, Evey Y F Zheng, et al.
JHEP Reports : Innovation in Hepatology|January 26, 2026
Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib - A phase II trial (PEMRAD)Grainne M O'Kane, Aruz Mesci, Raymond W Jang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2023
Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical TrialAbdulazeez Salawu, Ben X Wang, Ming Han, et al.
Clinical Colorectal Cancer|July 3, 2024
A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic CancerAlberto Hernando-Calvo, Ming Han, Olubukola Ayodele, et al.
Developmental Cell|May 17, 2025
Neurodevelopmental hijacking of oligodendrocyte lineage programs drives glioblastoma infiltrationYiyan Wu, Benson Z Wu, Yosef Ellenbogen, et al.
Nature Immunology|July 14, 2022
Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapyGiselle M Boukhaled, Ramy Gadalla, Heidi J Elsaesser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2023
Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell LymphomaJulio C Chavez, Francine M Foss, Basem M William, et al.
Pageof 4